Literature DB >> 10638758

Reduced vas deferens contraction and male infertility in mice lacking P2X1 receptors.

K Mulryan1, D P Gitterman, C J Lewis, C Vial, B J Leckie, A L Cobb, J E Brown, E C Conley, G Buell, C A Pritchard, R J Evans.   

Abstract

P2X1 receptors for ATP are ligand-gated cation channels, present on many excitable cells including vas deferens smooth muscle cells. A substantial component of the contractile response of the vas deferens to sympathetic nerve stimulation, which propels sperm into the ejaculate, is mediated through P2X receptors. Here we show that male fertility is reduced by approximately 90% in mice with a targeted deletion of the P2X1 receptor gene. Male mice copulate normally--reduced fertility results from a reduction of sperm in the ejaculate and not from sperm dysfunction. Female mice and heterozygote mice are unaffected. In P2X1-receptor-deficient mice, contraction of the vas deferens to sympathetic nerve stimulation is reduced by up to 60% and responses to P2X receptor agonists are abolished. These results show that P2X1 receptors are essential for normal male reproductive function and suggest that the development of selective P2X1 receptor antagonists may provide an effective non-hormonal male contraceptive pill. Also, agents that potentiate the actions of ATP at P2X1 receptors may be useful in the treatment of male infertility.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10638758     DOI: 10.1038/47495

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  114 in total

1.  Lack of run-down of smooth muscle P2X receptor currents recorded with the amphotericin permeabilized patch technique, physiological and pharmacological characterization of the properties of mesenteric artery P2X receptor ion channels.

Authors:  C J Lewis; R J Evans
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

2.  Signaling by extracellular nucleotides and nucleosides.

Authors:  P Illes; K N Klotz; M J Lohse
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2000-11       Impact factor: 3.000

3.  Quantal and non-quantal current and potential fields around individual sympathetic varicosities on release of ATP.

Authors:  M R Bennett; L Farnell; W G Gibson; Y Q Lin; D H Blair
Journal:  Biophys J       Date:  2001-03       Impact factor: 4.033

Review 4.  The developing relationship between receptor-operated and store-operated calcium channels in smooth muscle.

Authors:  Ian McFadzean; Alan Gibson
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

5.  Bretylium or 6-OHDA-resistant, action potential-evoked Ca2+ transients in varicosities of the mouse vas deferens: commentary on Jackson and Cunnane.

Authors:  J C McGrath
Journal:  Br J Pharmacol       Date:  2002-04       Impact factor: 8.739

6.  Distinct mechanisms underlying alpha1-adrenoceptor and P2x purinoceptor operated ATP release and contraction in the guinea-pig vas deferens.

Authors:  B Sperlágh; P Illes; Z Gerevich; A Köfalvi
Journal:  Neurochem Res       Date:  2001-09       Impact factor: 3.996

Review 7.  Neurotransmitter release mechanisms in sympathetic neurons: past, present, and future perspectives.

Authors:  V M Jackson; T C Cunnane
Journal:  Neurochem Res       Date:  2001-09       Impact factor: 3.996

8.  P2X receptor expression in mouse urinary bladder and the requirement of P2X(1) receptors for functional P2X receptor responses in the mouse urinary bladder smooth muscle.

Authors:  C Vial; R J Evans
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

9.  Male sexual dysfunction in mice bearing targeted mutant alleles of the PEA3 ets gene.

Authors:  M A Laing; S Coonrod; B T Hinton; J W Downie; R Tozer; M A Rudnicki; J A Hassell
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

10.  Investigation of neurotransmission in vas deferens from alpha(2A/D)-adrenoceptor knockout mice.

Authors:  Linda Cleary; Catherine Vandeputte; James R Docherty
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.